Safety assessment of a proprietary preparation of a novel Probiotic, Bacillus coagulans, as a food ingredient

J R Endres, A Clewell, K A Jade, T Farber, J Hauswirth, A G Schauss, J R Endres, A Clewell, K A Jade, T Farber, J Hauswirth, A G Schauss

Abstract

It has been demonstrated that some strains of Bacillus coagulans can survive extremes of heat, acidity of the stomach, and bile acids, to which commonly consumed probiotics are susceptible. A toxicological safety assessment was performed on a proprietary preparation of B. coagulans - GanedenBC(30) - a novel probiotic. Seven toxicologic studies were conducted and included: in vitro bacterial reverse mutation assay; in vitro chromosomal aberration assay; micronucleus assay in mice; acute and 90 day subchronic repeated oral toxicity studies were conducted in Wistar Crl:(WI) BR rats; acute eye and skin irritation studies were conducted in rabbits. The results of this toxicological safety assessment indicate that GanedenBC(30)B. coagulans does not demonstrate mutagenic, clastogenic, or genotoxic effects. Furthermore, the results of the acute and 90-day subchronic oral toxicity studies in rats resulted in the conclusion of a NOAEL greater than 1000 mg/kg per day. Since the concentration of the cell mass used in the 90-day study was 1.36 x 10(11) CFUs/g, this corresponds to 95.2 x 10(11) CFUs for a 70 kg human and since the suggested human dose is in the range of 100 x 10(6) to 3 x 10(9) CFUs, this gives a safety factor ranging from 3173 to 95,200 times. Based upon scientific procedures and supported by history of use, GanedenBC(30) is considered safe for chronic human consumption.

References

    1. Adami A., Cavazzoni V. Occurrence of selected bacterial groups in the faeces of piglets fed with Bacillus coagulans as probiotic. J. Basic Microbiol. 1999;39:3–9.
    1. Ames B.N. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat. Res. 1975;31:347–364.
    1. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr. 2001;73:399S–405S.
    1. Buchanan R.E., Gibbons N.E. eighth ed. Williams and Wilkens; Baltimore: 1974. Bergey’s Manual of Determinative Bacteriology.
    1. De Clerck E. Polyphasic characterization of Bacillus coagulans strains, illustrating heterogeneity within this species, and amended description of the species. Syst. Appl. Microbiol. 2004;27:50–60.
    1. De Vecchi E., Drago L. Lactobacillus Sporogenes or Bacillus Coagulans: misidentification or mislabelling? Int. J. Probiot. Prebiot. 2006;1:3–10.
    1. Donskey C.J. Effect of oral Bacillus coagulans administration on the density of vancomycin-resistant enterococci in the stool of colonized mice. Lett. Appl. Microbiol. 2001;33:84–88.
    1. Gandhi A.B. Probiotic lactic acid bacteria. East. Pharm. 1994;37:43.
    1. Graff S. Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition. Biol. Pharm. Bull. 2008;31:266–272.
    1. Hyronimus B. Acid and bile tolerance of spore-forming lactic acid bacteria. Int. J. Food Microbiol. 2000;61:193–197.
    1. Katsutoshi A.R. Effect spore-bearing lactic acid-forming bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats. Microbiol. Ecol. Health Dis. 2003;14:4–13.
    1. Lee Y.K. John Wiley & Sons; New York: 1999. Handbook of Probiotics.
    1. Lesbros-Pantoflickova D. Helicobacter pylori and probiotics. J. Nutr. 2007;137:812S–818S.
    1. Ljungh A., Wadstrom T. Lactic acid bacteria as probiotics. Curr. Issues Intest. Microbiol. 2006;7:73–89.
    1. Maron D.M., Ames B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983;113:173–215.
    1. McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008;14:2650–2661.
    1. Ouwehand A.C. Antiallergic effects of probiotics. J. Nutr. 2007;137:794S–797S.
    1. Patel M.A. Isolation and characterization of acid-tolerant, thermophilic bacteria for effective fermentation of biomass-derived sugars to lactic acid. Appl. Environ. Microbiol. 2006;72:3228–3235.
    1. Quigley E.M. Probiotics in irritable bowel syndrome: an immunomodulatory strategy? J. Am. Coll. Nutr. 2007;26:684S–690S.
    1. Rastall R.A. Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health: an overview of enabling science and potential applications. FEMS Microbiol. Ecol. 2005;52:145–152.
    1. Sanders M.E. Lactobacillus sporogenes is not a Lactobacillus probiotic. ASM News. 2001;67:385.
    1. Sarles W.B., Hammer B.W. Observations on Bacillus coagulans. J. Bacteriol. 1932;23:301–314.
    1. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Alim. Pharmacol. Ther. 2008;28:385–396.
    1. Tappenden K.A., Deutsch A.S. The physiological relevance of the intestinal microbiota-contributions to human health. J. Am. Coll. Nutr. 2007;26:679S–683S.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner